CTRI/2019/08/020818招募中未知
An open label non- randomized preliminary study comparing hand-held Narrow Band UVB device with standard whole body Narrow Band UVB therapy in treatment of localized vitiligo
AIIMS DELHI0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •a)Consecutive patients of localized vitiligo involving <=2% BSA or <=10 patches.
- •b)Patients >=18 years of age.
- •c)Patients who have not taken any topical therapy in last 2 weeks or systemic therapy in last 4 weeks
- •d)Patients giving consent for using hand held NB-UVB and whole body NB-UVB therapy
排除标准
- •a)Patients with rapidly spreading vitiligo.
- •b)Patients with recalcitrant forms of vitiligo i.e., lip-tip vitiligo, segmental vitiligo and with predominant leukotrichia on patches.
- •c)Patients with concomitant photo-aggravated dermatoses.
- •d)Patients who are unable to maintain the NB-UVB device.
研究者
相似试验
尚未招募
不适用
A preliminary study comparing daily use of home-based hand-held Narrow Band UVB comb device versus biweekly hospital-based excimer light therapy in treatment of localized vitiligoCTRI/2021/11/037885AIIMS New Delhi
未知
1 期
A Phase I, Open-label, Non-randomized Study, to Assess the Safety and Tolerability of Cediranib (AZD2171) in Combination With Cisplatin Plus a Fluoropyrimidine (Capecitabine or S-1) in Japanese Patients With Previously Untreated Locally Advanced or Metastatic Unresectable Gastric CancerGastric CancerJPRN-jRCT2080220881AstraZeneca
已完成
1 期
A study to characterize the impact of dietary modification on inavolisib associated hyperglycaemia and to assess the CYP3A4 induction potential of inavolisib using midazolam as a probe substrate in participants with incurable metastatic solid tumours previously treated with multiple (=2) lines of therapyMetastatic solid tumoursCancerISRCTN12839469F. Hoffmann-La Roche Ltd3
招募中
不适用
A Phase I, Open-label, Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of a Single Oral Dose of AZD9291 in Patients with EGFRm Positive NSCLC Whose Disease has Progressed on an EGFR TKIProgressive Non Small Cel Lung Cancer with positive epidermal growth factor receptor10038666NL-OMON45155Astra Zeneca5
进行中（未招募）
1 期
Study that tested S64315 plus different standard treatments in patients with breast cancerEUCTR2019-000998-23-ESInstitut de Recherches Internationales Servier